Last viewed:
RDUS
Prices are updated after-hours
RDUS
|
$17.64
-2.86%
-2.83%
280K
|
Health Technology
(0.0% 1d)
(-7.5% 1m)
(-40.2% 1y)
(0.0% 2d)
(-2.9% 3d)
(-5.7% 7d)
(29.02%
volume)
Earnings Calendar: 2024-01-04
Market Cap: $ 490,077,320
http://www.radiuspharm.com
Sec
Filling
|
Patents
| 383 employees
(US) Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.
breast cancer
cancer
education
endocrine
hormone
urea
women
osteoporosis
elacestrant
Drugs
Tymlos
(abaloparatide )
add to watch list
Paper trade
email alert is off
Press-releases
Radius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Published: 2024-04-16
(Crawled : 14:00)
- biospace.com/
RDUS
|
$17.64
-2.86%
-2.83%
280K
|
Health Technology
| 0.23%
| O: -1.65%
H: 0.98%
C: 0.69%
osteoarthritis
congress
world
presentation
tymlos
Second Quarter Fiscal 2024 Preliminary Results and Announcement of Earnings Date
Published: 2024-03-14
(Crawled : 21:00)
- globenewswire.com
RDUS
|
$17.64
-2.86%
-2.83%
280K
|
Health Technology
| -7.84%
| O: -1.57%
H: 3.98%
C: 2.6%
announcement
results
European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
Published: 2023-09-20
(Crawled : 15:00)
- prnewswire.com
RDUS
|
$17.64
-2.86%
-2.83%
280K
|
Health Technology
| -37.56%
| O: 0.07%
H: 2.72%
C: -0.85%
orserdu
breast
cancer
treatment
her2-
Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2
Published: 2023-07-21
(Crawled : 13:00)
- biospace.com/
RDUS
|
$17.64
-2.86%
-2.83%
280K
|
Health Technology
| -45.94%
| O: 0.21%
H: 0.67%
C: -0.98%
orserdu
chmp
her2
approval
positive
group
treatment
Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023
Published: 2023-05-26
(Crawled : 11:00)
- prnewswire.com
RDUS
|
$17.64
-2.86%
-2.83%
280K
|
Health Technology
| -38.9%
| O: 0.87%
H: 0.69%
C: -0.27%
orserdu
breast
asco
cancer
group
study
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting
Published: 2023-05-09
(Crawled : 13:00)
- biospace.com/
RDUS
|
$17.64
-2.86%
-2.83%
280K
|
Health Technology
| -35.81%
| O: -0.29%
H: 1.97%
C: 0.62%
elacestrant
breast
asco
cancer
group
meeting
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
Published: 2023-01-30
(Crawled : 12:20)
- prnewswire.com
RDUS
|
$17.64
-2.86%
-2.83%
280K
|
Health Technology
| -48.48%
| O: -1.99%
H: 2.44%
C: 0.48%
treatment
fda
breast
approval
cancer
orserdutm
elacestrant
esr1 mutation
elascestrant
her2-
her2
metastatic breast cancer
Stemline Therapeutics Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
Published: 2023-01-30
(Crawled : 12:20)
- biospace.com/
RDUS
|
$17.64
-2.86%
-2.83%
280K
|
Health Technology
| -48.48%
| O: -1.99%
H: 2.44%
C: 0.48%
treatment
fda
breast
approval
therapeutics
cancer
elacestrant
esr1 mutation
elascestrant
orserdu
her2-
her2
metastatic breast cancer
Stemline Therapeutics Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
Published: 2023-01-30
(Crawled : 13:00)
- biospace.com/
RDUS
|
$17.64
-2.86%
-2.83%
280K
|
Health Technology
| -48.48%
| O: -1.99%
H: 2.44%
C: 0.48%
treatment
fda
breast
approval
therapeutics
cancer
orserdutm
elacestrant
esr1 mutation
elascestrant
her2-
her2
metastatic breast cancer
Radius Health's TYMLOS® (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture
Published: 2022-12-20
(Crawled : 22:00)
- biospace.com/
RDUS
|
$17.64
-2.86%
-2.83%
280K
|
Health Technology
| -43.84%
| O: -0.7%
H: 3.3%
C: 1.73%
tymlos
treatment
fda
risk
bone
approval
osteoporosis
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0000899243-22-030031
4
2022-08-30
2022-08-11
Sell
U
8733538
0